BCG in Tower Hamlets. Luise Dawson Public Health Nurse

Similar documents
Patient Group Direction (PGD) for the Administration of BCG Vaccine

Administration of Tuberculin Purified Protein Derivative (PPD) 2TU per 0.1ml to patients attending BCG clinics with identified TB at risk factors.

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

PEDIA MANOR POLICY AND PROCEDURE MANUAL

7. BCG Vaccination HSE/HPSC. Guidelines on the Prevention and Control of Tuberculosis in Ireland IUATLD criteria

(a) Infection control program. The facility must establish an infection control program under which it--

Table 9. Policy for Tuberculosis Surveillance and Screening

Package leaflet: Information for the user. Tuberculin PPD RT23 "SSI" 2 T.U./0.1 ml, solution for injection Tuberculin PPD RT 23

BCG. Program Management. Vaccine Quality

IMMUNIZATION PROTOCOLS FOR PHARMACISTS. VARICELLA Live Virus Vaccine

Tuberculin Skin Testing

Tuberculin Purified Protein Derivative (Mantoux) Biological Page

Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018

FLORIDA DEPARTMENT OF JUVENILE JUSTICE DETENTION SERVICES FACILITY MEDICAL POLICIES

Standard Operating procedures for Gastric lavage/aspiration; Mantoux and Sputum induction (Adapted from the Childhood TB

Tuberculin PPD 100,000 units in 1 ml for Heaf Testing continues to be available.

Diagnosis Latent Tuberculosis. Disclosures. Case

Stop TB Poster (laminated copies are available from TB Control: )

2. Methods of Tuberculosis Screening

Interpretation of tuberculin skin-test results in the diagnosis of tuberculosis in children.

Tuberculosis Screening and Targeted Testing of College and University Students: Developing a Best Practice Approach:

Infections What is new and what is important?

Community pharmacy-based tuberculosis skin testing

TUBERCULOSIS INFECTIONS CONTROL

Tuberculosis and BCG

Tuberculosis Tools: A Clinical Update

HEALTHWEST PROCEDURE. No Revised by: Effective: December 1, 1995 Revised: April 19, 2017 Environment of Care Committee

Summary of product characteristics As per Annexure C. SUMMARY OF PRODUCT CHARACTERISTICS Doc. No. SPC/71108 Ver.1

New NICE guideline updates recommendations for diagnosing latent tuberculosis

SAFETY AND IMMUNOGENICITY OF BACILLUS CALMETTE-GUERIN VACCINE IN CHILDREN BORN TO HIV-1 INFECTED WOMEN

Vaccination to protect against shingles

Tuberculosis Screening Protocol For Use In Marin County School Settings

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Fundamentals of Tuberculosis (TB)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Contact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan

Update on Tuberculosis Skin Testing of Children

Tuberculosis in Malta and the school BCG vaccination programme

ATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Director, University Health Services. Medical Director

Northwestern Polytechnic University

Summary of Immunization Options

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines

Self-Study Modules on Tuberculosis

INDEX CASE INFORMATION

July 13, 1990 / 39(RR-10);7-20

Management of Pediatric Tuberculosis in New Jersey

IMPORTANT INFORMATION FOR HEALTHCARE PROFESSIONALS ON SAFETY AND RISK MINIMISATION FOR INFLIXIMAB

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

Pre-administration checklist for Fluenz Tetra nasal spray vaccine

COFM Immunization Policy

UNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL VEDOLIZUMAB (ENTYVIO)

Papers from WHO Fellows NTI Bulletin 2004,40/3&4, 64-69

Health Care Workers (HCWs) in Ireland should have 2 doses of MMR vaccine. Two of the cases in recent outbreaks in Ireland were HCWs.

2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016

Examples COMPLETED. Immunization Forms

BCG Vaccine. For Intradermal Injection

Keck Graduate Institute

CONJUGATE MENINGOCOCCAL (ACWY) VACCINE

EPI Case Study 2: Reliability, Validity, and Tests of Agreement in M. Tuberculosis Screening Time to Complete Exercise: 30 minutes

Required Certificate of Immunization

Training slides for Tuberculin Skin Testing (TST)

Student Health Requirements Master of Arts, Biomedical Sciences Program

CUSOM Student Health Immunization Requirements

Dear Student, Welcome to the University of Chicago!

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014

Therapy for Latent Tuberculosis Infection

Why need to havetb Clearance. To Control and Prevent Tuberculosis

The duration of protective immunity following immunisation is unknown, but is believed to be in excess of five years.

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

CLINICAL GUIDELINE FOR NEONATAL BCG VACCINATION V3.0

Children and Young Peoples Clinical Programme Group IMMS 03

Interpretation of Mantoux Tuberculin Test Activation Date: 09-Sep-2014 Review Date: 15-Jun-2018

PGD for the administration of:

Streptococcus pneumoniae CDC

Tuberculosis (TB) Fundamentals for School Nurses

LATENT TUBERCULOSIS. Robert F. Tyree, MD

These guidelines have been drawn up to ensure a coherent practice from all neonatal staff involved in immunisation.

Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control in Dumfries and Galloway.

Pneumococcal Disease and Pneumococcal Vaccines

757 College Way, Claremont, CA (909) (909) F

Joint Commission 2010 Guidelines: Influenza Vaccinations for Health-Care Workers

LESSON ASSIGNMENT. After completing this lesson, you should be able to:

LATENT TUBERCULOSIS SCREENING AND TREATMENT:

Trust Guideline for the Prevention of Tuberculosis and Management of Tuberculosis Exposure in Health Care Workers

Student Health and Immunization Record

Isoniazid Preventive Therapy (IPT)

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

Contact Investigation and Prevention in the USA

Core Curriculum on Tuberculosis: What the Clinician Should Know

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

INFECTIOUS DISEASES Tuberculosis (TB): targeting our interventions

NICE guideline Published: 13 January 2016 nice.org.uk/guidance/ng33

Vice Chancellor, Health Affairs & Dean, School of Medicine Vice Chancellor & Dean s Office Origination Date: 05/20/2013 Date of Revision: Scope:

Approaches to LTBI Diagnosis

Seasonal Influenza. Provider Information Sheet. Infectious Disease Epidemiology Program

Peggy Leslie-Smith, RN

IMOVAX POLIO POLIOMYELITIS VACCINE (INACTIVATED) Suspension for injection in prefilled syringe

New Entrant Screening and Latent TB Get screened and find out if you have TB infection before you develop TB disease!

Transcription:

BCG in Tower Hamlets Luise Dawson Public Health Nurse

Coverage levels of BCG for infants under 1 year 100% 90.9% 95.5% 95.0% 98.7% 90% 81% 82% 80% 70% 60% 50% 40% 30% 20% 10% 0% March 0708 March 0809 March 0910 March 1011 March 1112 March 1213

BCG should also be offered to: previously unvaccinated children aged one to 16 years with a parent or grandparent who was born in a country where the annual incidence of TB is 40/100,000 or greater. previously unvaccinated tuberculin-negative individuals under 16 years of age who are contacts of cases of respiratory TB previously unvaccinated, tuberculin-negative individuals under 16 years of age who were born in or who have lived for a prolonged period (at least three months) in a country with an annual TB incidence of 40/100,000 or greater. 3

Countries with TB rates >40/100,000 are considered to be high risk areas for immunisation purposes http://www.hpa.org.uk/web/hpaweb&hpawebstandard/hpaweb_c/1195733837507 - for the current comprehensive list on on countries in the high risk areas. 4

Tuberculin skin test A tuberculin skin test is necessary prior to BCG vaccination for: all individuals aged six years or over infants and children under six years of age with a history of residence or prolonged stay (more than three months) in a country with an annual TB incidence of 40/100,000 or greater those who have had close contact with a person with known TB those who have a family history of TB within the last five years BCG can be given to children <6 years of age without a skin test unless they fall into any of the above categories 5

Mantoux test The standard tuberculin skin test for use in the UK is the Mantoux test using 2TU/0.1ml tuberculin PPD. Tuberculin PPD is manufactured by Statens Serum Institut (SSI). Tuberculin PPD from SSI is not licensed medicine in the UK (although it has a marketing authorisation for use in other European countries). 6

Administration of the Mantoux test Intradermal injection (sometimes referred to as intracutaneous administration) normally on the flexor surface of the left forearm at the junction of the upper third with the lower two-thirds 7

Reading Mantoux test The results should be read 48 to 72 hours after the test is taken, but a valid reading can usually be obtained up to 96 hours later The transverse diameter of the area of induration at the injection site is measured with a ruler; the area of erythema is irrelevant The size of the induration should be recorded in millimetres and NOT just as a negative or positive result 8

Interpretation of the Mantoux test Diameter of induration Positivity Interpretation < 6mm Negative - no significant hypersensitivity to tuberculin protein 6mm to 15mm Positive hypersensitive to tuberculin protein >15mm Strongly positive - strongly hypersensitive to tuberculin protein Previously unvaccinated individuals may be given BCG provided there are no contraindications Should not be given BCG* - May be due to previous TB infection or BCG or exposure to non-tuberculous mycobacteria Suggests tuberculosis infection or disease. Should be referred for further investigation and supervision (which may include preventive chemotherapy) * No further action if test was performed as part of an immunisation programme. Referral to chest clinic may be indicated if test was performed to screen for TB infection and the person has not been previously vaccinated with BCG. 9

Immunocompromised individuals BCG is contraindicated in those immunocompromised by virtue of disease or treatment:» patients receiving corticosteroid or other immunosuppressive treatment, including general radiation. Inhaled steroids are not a contraindication» malignant condition such as lymphoma, leukaemia, Hodgkin s disease or other tumour of the reticuloendothelial system» symptomatic HIV-positive individuals» Other known or suspected HIV positive in low risk countries such as the UK, regardless of clinical status. Where vaccination is indicated, for example infants born to HIV-positive mothers, this can be administered after two appropriately timed negative postnatal PCR tests for HIV infection 10

Previous BCG vaccination Other contraindications Past history of TB Induration of 6mm or more following Mantoux (SSI) tuberculin skin testing confirmed anaphylactic reaction to a component of the vaccine neonates in a household where an active TB case is suspected or confirmed (should be investigated for TB infection first) As a precaution not recommended during pregnancy, unless benefits outweigh risks (no recorded reports of the BCG vaccine affecting pregnancy) 11